Skip to main content
Equibles
BHVN logo

BHVN · Biohaven Ltd.

Track BHVN — free

Use BHVN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BHVN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$14.12 +0.62 (+4.59%)
Market Cap
$2.04B
Shares
151.04M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.50 Open$13.96 Day$13.26–14.52 52W close$7.79–18.11 Avg vol 30d1.9M Short int18.2M · 12.0% float · 9.3d Short vol66% Last earningsMay 27, 2026 DataSep 2022–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Aug 27, 2026 Est · unconfirmed · in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg −6%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 55%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −8%
trailing
6-month return +17%
trailing
YTD return +20%
this year
Relative strength +6%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +51 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.04% of float · ▼ -6.0% MoM · 9.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
292 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
EPS growth +26%
Y/Y
Free cash flow $-610.2M
Balance sheet $230.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 89%
annualized · 1-yr
Max drawdown −57%
past year
ATR 6.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
−6% Bearish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
55% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +51 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.04% of float · ▼ -6.0% MoM · 9.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
292 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8 Now $14 · 55% Range high $18
vs 200-day avg +19% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, marketable securities and restricted cash $270.5M as of June 30, 2026 —
Non-GAAP adjusted net loss non-GAAP $118.1M the three months ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP net loss -137.31M
+19.16M non-cash share-based compensation expense
+0K loss from change in fair value of derivatives
= Non-GAAP adjusted net loss -118.15M
Non-GAAP adjusted net loss per share non-GAAP $0.78 the three months ended June 30, 2026 —
Non-GAAP adjusted net loss per share — basic and diluted non-GAAP -$1.48 Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BHVN
Biohaven Ltd.
this stock
$2.04B +19.6% — — 12.0%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
292
% held
95.2%
Net QoQ
-695.9K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
56
View
Short & Settlement
Short Interest Falling
Shares short
18.2M
Days to cover
9.3d
Change
-1.2M sh
View
Short Volume
Short vol %
66%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
100
Value
$1.5K
As of
Jul 24, 2026
View
Off-Exchange
Off-exchange %
41.4%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-738.8M
EPS diluted
$-6.86
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
14
View
Proposed Sales
Value
$459.7K
Shares
11.0K
Filed
Dec 29, 2023
View
Earnings & Events
Earnings Calls
Last call
May 27, 2026
View

Performance

5D 20D 120D MTD YTD
BHVN -9.1% -7.9% +17.2% +0.0% +19.6%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY -7.1% -11.2% +6.0% -2.1% +7.7%
Key facts CIK 1935979 CUSIP G1110E107 13F (30d) 266 filings 261 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)